Richard Eastman

Oct 24, 2023 | biorxiv.org | Richard Eastman |Radda Rusinova |Xi-Ping Huang |Karl F Herold

AbstractSince it was proposed as a potential host-directed antiviral agent for SARS-CoV-2, the antiparasitic drug ivermectin has been investigated thoroughly in clinical trials, which have provided insufficient support for its clinical efficacy. To examine the potential for ivermectin to be repurposed as an antiviral agent, we therefore undertook a series of preclinical studies.